Cancer Screening Program - CaSP

Bringing comprehensive genomic profiling to patients with advanced and incurable cancer and helping identify potential matches for patients to clinical trials with new targeted therapies.

Download Omico CaSP Information Sheet

What is CaSP?

Cancer Screening Program (CaSP) is the screening program associated with PrOSPeCT, and provides free Comprehensive Genomic Profiling (CGP) to patients in Australia with incurable and advanced cancer, to identify potential matches for patients to clinical trials with new targeted therapies.

CaSP has three parts

Part 1: Screening 23,000 patients with advanced or incurable cancer

Screening of up to 23,000 advanced or incurable cancer patients using Comprehensive Genomic Profiling (CGP) at no cost to the patient.

We use genomic profiling to analyse the molecular characteristics of a patient’s tumour and we gather as much genetic and clinical information as we can to help us identify specific characteristics about the tumour.

The genomic profiling is carried out by NATA accredited pathology laboratories.

A team of our experts review the genomic profile of the tumour with other clinical and patient information. A Molecular Oncology Board (MOB) Report provides the  genomic profiling pathology report to the referring clinician, as well as potential treatments and trials for patients. 

Once a patient has provided written consent to participate in CaSP, it typically takes 8-10 weeks for the referring clinician to receive the MOB report. Patients indicated as urgent by the referring clinician will be fast-tracked, with MOB reports returned in 5-6 weeks.

2: An observational cohort study of people enrolled in CaSP

CaSP does not deliver any specific intervention and is not a clinical trial. Its primary purpose is to make Comprehensive Genomic Profiling (CGP) more broadly available to people with an unmet need and to use that information to link people to potential clinical trials.

It is important that the information collected by CaSP be used to guide how CGP is implemented in Australia and to evaluate what use it provides to the community.


Part 3: Research Registry and Biobank

CaSP will establish a research registry and bioresource to facilitate the observational cohort study and provide a resource for future use including clinical trial and treatment matching, and epidemiological and public health research studies to facilitate ongoing research into cancer and its treatment.

Who can participate in CaSP?

Participation in CaSP requires referral from a patient’s treating oncologist.

Patients aged 16 yrs and older with an advanced or incurable solid or blood cancer who are willing and fit enough to participate in a clinical trial are eligible.

Your treating oncologist will assess your eligibility, complete the CaSP referral forms, and provide all relevant information. Refer to the CaSP information sheet for all inclusion and exclusion criteria.

What does participation involve?

  • Agreeing to all parts of CaSP
  • Consenting to the access of samples held by pathology centres to perform CGP
  • Consenting to the access to your health records
  • Evaluation of molecular and clinical information for trial matching or molecular guided treatment
  • Donating blood samples and other tissues
  • Completing questionnaires
  • Consent for access for Medicare / PBS data

Interested in knowing more?

Get in touch